180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was given for research conducted by and a paper written by Williams. The paper, which was published in “Proceedings of the National Academy of Science, USA,” was titled “Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.” The research identified the collagen VI pathway, which 180 Life Sciences is now pursuing in preclinical studies. The findings reported in the paper were compiled as a result of Williams’s work as a member of Professor Jagdeep Nanchahal’s research team; Nanchahal is chairman of 180 Life Sciences’ Clinical Advisory Board. The announcement noted that Dr. Thomas Layton, another member of Nanchahal’s research team in Oxford, was named as a joint recipient of the International Dupuytren Award in both 2020 and 2019. Nanchahal and his clinical research team received the 2019 award for the publication of the phase 2a clinical trial data. “This pivotal research for which Dr. Williams has received this award, was published in a high-impact journal and provides insight into Collagen VI pathways to identify novel potential therapeutic targets for fibrotic diseases,” said 180 Life Sciences CEO James Woody in the press release. “This research from our team, led by Professor Jagdeep Nanchahal, is the foundation of our program to develop new treatments for fibrosis.”
To view the full press release, visit https://ibn.fm/1Kp5V
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
